Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Febuxostat on Disease Progression and CIMT in CKD
NCT06997952Phase 1Completed
- Sponsor
- Ain Shams University
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of febuxostat in chronic kidney disease (CKD) and hyperuricemia (2 arms), sponsored by Ain Shams University. Primary endpoints: Estimated Glomerular Filtration Rate at 12 weeks and Proteinuria at 12 weeks. Started May 2024; status: completed.
02
Drugs
febuxostat
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on NCT06997952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997952.